Table 1.

Suggested Convalescent Plasma Trial Design

Possible trial arms

•Placebo

•Convalescent plasma infusion from donor with low titer

•Convalescent plasma infusion from donor with high titer

•Fresh frozen plasma infusion

Potential laboratory monitoring of patient, suggested before infusion and at multiple time points (before and after therapy)

•COVID-19–specific IgG and IgM

•Lymphocyte flow cytometry

•Cytokine panel

•Single-cell RNA sequencing

•Radiographic improvement

Evaluate effectiveness of convalescent therapy based on pretherapy respiratory status/oxygen requirement

•No supplemental oxygen

•Nasal cannula oxygen supplementation

•Noninvasive ventilation

•Invasive ventilation

Evaluate effectiveness of convalescent therapy based on time since symptom onset and current active viral replication as evaluated by viral culture or PCR.

Abbreviations: COVID-19, coronavirus disease 2019; Ig, immunoglobulin; PCR, polymerase chain reaction.